2023-509086-20-00已完成1 期
A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEALTHY SUBJECTS.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Gene Marcantonio
Scientific
Armgo Pharma Inc.
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
A SINGLE CENTER, BLINDED, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF THE EFFECT OF CRx-139 ON POCKET DEPTH AND INFLAMMATORY CYTOKINES COMPARED TO PLACEBO IN SUBJECTS WITH SEVERE ADULT PERIODONTITIS - CRx-139-PESEVERE ADULT PERIODONTITISEUCTR2005-001440-23-SECombinatoRx, Inc.
进行中（未招募）
不适用
A MULTI CENTER, SINGLE-BLIND, PLACEBO-CONTROLLED PHASE 2STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRAVENOUS CD-NPIN THE TREATMENT OF PATIENTS WITH ACUTE DECOMPENSATEDHEART FAILURE (ADHF) - NIL-CDNP-CT005MedDRA version: 9.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureAcute Decompensated Heart FailureEUCTR2008-008384-10-DEile Therapeutics, Inc.75
进行中（未招募）
不适用
A SINGLE CENTER, SINGLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF THE EFFECT OF CRx-102 COMPARED TO PLACEBO ON SERUM C-REACTIVE PROTEIN (CRP) AND INFLAMMATORY CYTOKINES IN SUBJECTS WITH SEVERE ADULT PERIODONTITIS - CRx-102EUCTR2004-003755-39-SECombinatoRx, Inc60
招募中
3 期
A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUSsystemic lupus erythematosusJPRN-jRCT2071230031Yoshiya Tanaka24
进行中（未招募）
不适用
A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITISLupus NephritisjRCT2011210059Nippon Shinyaku Co., Ltd.24